These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33236378)

  • 1. Parafoveal Change and Dopamine Loss in the Retina with Parkinson's Disease.
    Lee JY; Ahn J; Shin JY; Jeon B
    Ann Neurol; 2021 Feb; 89(2):421-422. PubMed ID: 33236378
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ophthalmic disorders as a manifestation of Parkinson's disease].
    Chesnokova NB; Pavlenko TA; Ugrumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):124-131. PubMed ID: 29053133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minor retinal degeneration in Parkinson's disease.
    Huang YM; Yin ZQ
    Med Hypotheses; 2011 Feb; 76(2):194-6. PubMed ID: 20933338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Peek into Parkinson's Disease Progression through Human Dopamine Neurons in a Dish.
    Yang N; Yue Z
    Trends Neurosci; 2018 Feb; 41(2):74-76. PubMed ID: 29248177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Bonet-Ponce L; Singleton AB
    Mov Disord; 2017 Aug; 32(8):1164. PubMed ID: 28631854
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine depletion alters macroscopic network dynamics in Parkinson's disease.
    Shine JM; Bell PT; Matar E; Poldrack RA; Lewis SJG; Halliday GM; O'Callaghan C
    Brain; 2019 Apr; 142(4):1024-1034. PubMed ID: 30887035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron, Dopamine, and α-Synuclein Interactions in at-Risk Dopaminergic Neurons in Parkinson's Disease.
    Song N; Xie J
    Neurosci Bull; 2018 Apr; 34(2):382-384. PubMed ID: 29380248
    [No Abstract]   [Full Text] [Related]  

  • 11. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease.
    Nguyen-Legros J
    Surg Radiol Anat; 1988; 10(2):137-44. PubMed ID: 3135618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of microRNA-375 ameliorates the damage of dopaminergic neurons, reduces oxidative stress and inflammation in Parkinson's disease by inhibiting SP1.
    Cai LJ; Tu L; Li T; Yang XL; Ren YP; Gu R; Zhang Q; Yao H; Qu X; Wang Q; Tian JY
    Aging (Albany NY); 2020 Jan; 12(1):672-689. PubMed ID: 31927536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities.
    Uhl GR
    Ann Clin Transl Neurol; 2019 Feb; 6(2):406-415. PubMed ID: 30847375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of mouse models of Parkinson's disease.
    Bobela W; Zheng L; Schneider BL
    Curr Protoc Mouse Biol; 2014 Sep; 4(3):121-39. PubMed ID: 25723963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of choosing a preclinical model that reflects what happens in Parkinson's disease.
    Segura-Aguilar J
    Neurochem Int; 2019 Jun; 126():203-209. PubMed ID: 30922924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common pathophysiology affecting diabetic retinopathy and Parkinson's disease.
    Tian T; Li Z; Lu H
    Med Hypotheses; 2015 Oct; 85(4):397-8. PubMed ID: 26141638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-specific overexpression of COMT in dopaminergic neurons of Parkinson's disease.
    Kuzumaki N; Suda Y; Iwasawa C; Narita M; Sone T; Watanabe M; Maekawa A; Matsumoto T; Akamatsu W; Igarashi K; Tamura H; Takeshima H; Tawfik VL; Ushijima T; Hattori N; Okano H; Narita M
    Brain; 2019 Jun; 142(6):1675-1689. PubMed ID: 31135049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.
    Nam JH; Park ES; Won SY; Lee YA; Kim KI; Jeong JY; Baek JY; Cho EJ; Jin M; Chung YC; Lee BD; Kim SH; Kim EG; Byun K; Lee B; Woo DH; Lee CJ; Kim SR; Bok E; Kim YS; Ahn TB; Ko HW; Brahmachari S; Pletinkova O; Troconso JC; Dawson VL; Dawson TM; Jin BK
    Brain; 2015 Dec; 138(Pt 12):3610-22. PubMed ID: 26490328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.